Answers are grounded in this paper and cite their sources.
Drug sensitivity testing discovers effective treatments in patients with refractory bone sarcomas, suggesting new therapeutic options.
Drug sensitivity testing of PDCs from bone sarcomas is a valuable tool for a rapid identification of potential treatments, in otherwise genetically complex group of tumors where genome-based assays are difficult to implement. Clones with different phenotypes can outgrow in PDC cultures and can represent clonal evolution that give raise to tumor recurrence.
No takes yet. Share an insight, caveat, or question.
Linder-Stragliotto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: